The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
This article reports on experimental research that involves procuring stem cells from the cornea, growing them outside the eye, and then transplanting them to the diseased eye. Although this is exciting, it is quite early in the experimental stages and its application is limited to certain corneal diseases....
Alcon has suffered with its LADARVision system recalls and lawsuits, and has looked particularly troubled following AMO's acquisition of VISX. Although AMO/VISX remains the market leader for refractive correction, the Allegretto represents new technology with potential advantages in terms of accuracy...
This article describes a new drug that has a potential to address pathophysiology of wet macular degeneration on broader basis than treatments we use currently. This drug inhibits not only angiogenesis but also fibrosis formation and inflammation which remain a significant problem even with successful...
Current understanding of AMD recognizes 3 causative factors: angiogenesis, some inflammation and fibrosis. Both PDT and ranibizumab address the same problem of inhibiting of new vessels growth. Ranibizumab has been shown significantly superior to PDT. Its ability to stop new vessels and reduce...
This article reports that the FDA approved an Investigative New Drug application for an anti-integrin (JSM 6427) in the treatment of age-related macular degeneration (AMD). This would allow testing in preclinical trials of this compound for neovascular AMD. This could be another medication...
The FDA has just approved a "bifocal LASIK" technique from Advanced Medical Optics using their CustomVue Excimer laser platform. It has been approved as " a new device". In actuality, it is neither a new device nor does it provide bifocal vision.
The FDA recently approved a CustomVue Monovision LASIK surgery (AMO; EYE) for the treatment of presbyopia. The premise is to treat one eye for distance and allow the other (partially treated) for near vision reducing the need for spectacles. This is nothing new and has been used for years as ...
AMO (EYE) recently outbid a private equity firm to acquire Bausch & Lomb (BOL). It has the potential to add to AMO's market share and establish it as the force in Ophthalmology.
Currently the ophthalmic device market is organized into an oligopoly including Alcon, AMO and Bausch. AMO has shown fairly dramatic growth with its acquisition of VISX, Intralase and Wavefront Sciences. However, AMO's potential acquisition of Bausch is on a grander scale. There are...
In this news release presented today, this leading ophthalmic journal reports that AMO has presented the highest bid for the purchase of Bausch and Lomb.